StoxRadar is free — only 218 spots left in beta.

SPY$773.93-0.42%QQQ$747.58-1.34%DIA$511.65+0.12%IWM$277.57-0.05%AAPL$340.42+1.11%MSFT$522.61-1.35%NVDA$230.48-2.94%AMZN$254.06-2.25%GOOGL$348.29-0.63%META$720.89-0.06%TSLA$375.00-0.74%JPM$331.42+0.56%GLD$378.62+0.73%BTC$36.12-2.06%IBIT$46.26-2.01%SPY$773.93-0.42%QQQ$747.58-1.34%DIA$511.65+0.12%IWM$277.57-0.05%AAPL$340.42+1.11%MSFT$522.61-1.35%NVDA$230.48-2.94%AMZN$254.06-2.25%GOOGL$348.29-0.63%META$720.89-0.06%TSLA$375.00-0.74%JPM$331.42+0.56%GLD$378.62+0.73%BTC$36.12-2.06%IBIT$46.26-2.01%

StoxRadar is free.

RUBY

RUBY

NASDAQ

Rubius Therapeutics, Inc.

Healthcare · Biotechnology

$0.06
+0.00+2.70%
Day Range: $0.06 – $0.06
Market Cap
$0
Volume
755,858
52W High
$0.38
52W Low
$0.00
P/E Ratio
-0.02
EPS (TTM)
$-2.56
Div Yield
—
Beta
2.21

Price History

11-1611-2712-0512-1312-21$0.0115$0.023$0.0345$0.046$0.0575

Learn Why It Moved

Educational concepts related to this stock

Biotech Catalyst

Biotech stocks are often driven by FDA approvals, trial results, and regulatory news. Learn how binary catalysts work.

Insider Activity

Check if insiders have been buying or selling. Insider buying is one of the strongest signals in small cap trading.

Dilution Risk

Check SEC filings for active shelf registrations. Dilution is the #1 risk in small cap trading.

Explore Small Cap Academy

Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.

CEO
Laurence A. Turka
Employees
6
Headquarters
Cambridge, US
IPO Date
2018-07-18
BETA

Get started for full access.